Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Journal of Clinical Tuberculosis and Other Mycobacterial Diseases|April 22, 2026
Case reports: Pulmonary destructive lesions caused by ankylosing spondylitisSenlin Zhan, Hongyi Zhang, Qiaoli Peng, et al.
Journal of Clinical Tuberculosis and Other Mycobacterial Diseases|December 24, 2025
Treatment outcomes among patients with mycobacterial blood stream infection in a tertiary hospital:a retrospective study form 2019 to 2023Liangzi Yang, Houming Liu, Senlin Zhan, et al.
BMC Pulmonary Medicine|April 11, 2025
Case report: pulmonary lymphoepithelial carcinoma mimicking tuberculosisSenlin Zhan, Changyin Feng, Kaihua Pang, et al.
Drug Discoveries & Therapeutics|April 14, 2022
Prospects of contezolid (MRX-I) against multidrug-resistant tuberculosis and extensively drug-resistant tuberculosisMin Yang, Senlin Zhan, Liang Fu, et al.
Therapeutics and Clinical Risk Management|June 1, 2022
Extensive Radiological Manifestation in Patients with Diabetes and Pulmonary Tuberculosis: A Cross-Sectional StudySenlin Zhan, Xiong Juan, Tantan Ren, et al.
Infection and Drug Resistance|May 31, 2022
Linezolid-Associated Neuropathy in Patients with MDR/XDR Tuberculosis in Shenzhen, ChinaPeize Zhang, Wei Li, Miaona Liu, et al.
Archives of Microbiology|November 19, 2024
JIB-04, an inhibitor of Jumonji histone demethylase as a potent antitubercular agent against Mycobacterium tuberculosisPei Li, Qiwen Huang, Yanling Xie, et al.
Scientific Reports|May 2, 2024
Risk factors associated with pulmonary hypertension in patients with active tuberculosis and tuberculous destroyed lung: a retrospective studyWeijian Liu, Yuxiang Xu, Liangzi Yang, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 21, 2025
Safety, feasibility and rifapentine plasma concentration in Chinese children with 1 month of daily rifapentine plus isoniazid for tuberculosis infectionWeijian Liu, Tian He, Senlin Zhan, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 13, 2026
Fixed-Dose Rifapentine-Isoniazid (1HP) for Tuberculosis Preventive Treatment in Chinese Adults: A Prospective Real-World Safety and Pharmacokinetic StudySenlin Zhan, Weijian Liu, Liangzi Yang, et al.
Pageof 2